Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Randomized Blinded Trial of Investigational Therapeutics for Hospitalized Adults With COVID-19 (EU/UK)
2020-001052-18Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remdesivir and baricitinib in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University of Minnesota. Primary endpoint: Time to recovery. Started Mar 2020; status: completed.
02
Drugs
remdesivirbaricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001052-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001052-18.